Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SBP-9330
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : $9.0 million
Deal Type : Funding
$9 Million NIH Grant Advances Drug to Treat Nicotine Addiction
Details : The net proceeds will fund longer toxicology studies and manufacturing of SBP-9330, a small molecule targeting mGlu2 receptor, to support planned Phase 2 trials for nicotine cessation.
Brand Name : SBP-9330
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 06, 2024
Lead Product(s) : SBP-9330
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : National Institute on Drug Abuse
Deal Size : $9.0 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $1.9 million
Deal Type : Funding
Details : The grant will be used for the preclinical development of novel therapeutic options such as positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGlu2) for the treatment of alcohol use disorder (AUD).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 07, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $1.9 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?